- Researchers investigated whether inhibiting microRNA-132 with CDR132L could limit adverse cardiac remodeling in patients following a recent myocardial infarction.
- This phase 2 trial randomized 294 patients with systolic dysfunction to receive three intravenous doses of CDR132L or placebo.
- At six months, left ventricular end-systolic volume index did not differ significantly between the 5 or 10 mg/kg groups and placebo.
- The study concluded that CDR132L was well tolerated but failed to significantly improve cardiac function or volume compared to placebo.
- Future research will evaluate CDR132L in chronic heart failure and patients with advanced adverse remodeling at baseline.
Targeting Epigenetic Drivers of Post-Infarction Remodeling
Adverse left ventricular remodeling after acute myocardial infarction remains a primary driver of heart failure, affecting nearly one-third of survivors despite modern reperfusion and guideline-directed therapies [1, 2]. While current treatments target neurohormonal pathways, attention has turned to epigenetic regulators like microRNA-132, a short, non-coding RNA molecule implicated as a central mediator of pathological cardiac hypertrophy and fibrosis [3, 4]. This has led to the development of therapies like CDR132L, an antisense oligonucleotide, which is a synthetic strand of nucleic acid designed to bind and inhibit a specific RNA target. The HF-REVERT trial was a phase 2 study designed to evaluate if inhibiting microRNA-132 with CDR132L could mitigate adverse remodeling [5, 6]. In 294 patients recently post-MI, three intravenous doses of CDR132L at 5 mg/kg or 10 mg/kg were compared to placebo. Despite a strong preclinical rationale [7, 8], the study found no significant difference at six months in its primary endpoint, the change in left ventricular end-systolic volume index, or in key secondary measures like ejection fraction and N-terminal pro B-type natriuretic peptide [5].
HF-REVERT Trial Design and Patient Demographics
The HF-REVERT trial was a multinational, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of the microRNA-132 inhibitor CDR132L in a clinically relevant setting. To intervene during the critical early window of adverse cardiac remodeling, investigators enrolled 294 patients with left ventricular systolic dysfunction within 3 to 14 days of their myocardial infarction. The final analysis was conducted on a modified intention-to-treat population of 280 patients (245 men and 35 women) who received at least one dose of the study drug. Participants were randomized to one of three arms: intravenous CDR132L at 5 mg/kg, CDR132L at 10 mg/kg, or a matching placebo. The assigned treatment was administered as three separate infusions at 4-week intervals. Importantly, all patients continued to receive guideline-directed medical therapy, positioning CDR132L as an adjunct to the current standard of care for post-infarction management.
Primary and Secondary Structural Outcomes
The trial's primary efficacy endpoint was the percentage change in left ventricular end-systolic volume index at 6 months, a standard metric for tracking the progression of adverse cardiac remodeling. While all three groups (both CDR132L doses and placebo) demonstrated an improvement in this index, likely reflecting the benefit of standard post-MI care, the core objective was not met. The analysis revealed no significant difference in the change in left ventricular end-systolic volume index between either CDR132L group and the placebo group. This primary finding was reinforced by the results for key secondary endpoints. Measures of cardiac function, including left ventricular ejection fraction and global longitudinal strain (a sensitive echocardiographic measure of myocardial deformation), also showed no significant improvement with CDR132L compared to placebo. Similarly, levels of N-terminal pro B-type natriuretic peptide, a biomarker of cardiac wall stress, did not differ significantly between the treatment and placebo arms. Collectively, these results indicate that inhibiting microRNA-132 in this patient population did not produce measurable benefits in cardiac structure, function, or hemodynamic stress beyond those achieved with standard therapy at six months.
Safety Profile and Exploratory Signals
A crucial outcome for any new therapeutic modality is its safety, and on this front, the findings were reassuring. The administration of CDR132L was well tolerated, with no hepatic, renal, hematologic, or cardiac toxicity signals identified during the study. This favorable safety profile is an important finding for the antisense oligonucleotide class of drugs. Although the trial did not meet its primary or secondary endpoints in the overall population, prespecified exploratory analyses yielded a potentially important observation. These analyses suggested that CDR132L treatment may confer benefits in the subgroup of patients who presented with more advanced adverse remodeling at baseline. This signal, while not conclusive, raises the possibility that the therapy could be more effective in patients with a greater degree of established cardiac damage. Based on the drug's tolerability and this exploratory finding, the authors conclude that further evaluation of CDR132L is warranted, perhaps in populations with chronic heart failure where the remodeling process is more advanced and entrenched.
References
1. Richards M, Wang P, Wong LL. ‘Micro’-Managing Heart Failure: Restoring that Which was Lost in Translation. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3188
2. Marcos‐Garcés V, Bertolín‐Boronat C, Merenciano-Gonzalez H, et al. Left Ventricular Remodeling After Myocardial Infarction—Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210964
3. Batkai S, Genschel C, Viereck J, et al. Abstract 15096: miR-132 Inhibition Shows Anti-Hypertrophic Effects in Preclinical Heart Failure Models and in Exploratory Pharmacodynamic Parameters of a First-in-Human Phase 1b Clinical Trial. Circulation. 2023. doi:10.1161/circ.148.suppl_1.15096
4. Bátkai S, Genschel C, Viereck J, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. European Heart Journal. 2020. doi:10.1093/eurheartj/ehaa791
5. Bauersachs J, Solomon SD, Anker SD, et al. The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.. Nature medicine. 2026. doi:10.1038/s41591-026-04408-4
6. Bauersachs J, Solomon SD, Anker SD, et al. Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale and Design of the HF-REVERT Trial. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3139
7. Batkai S, Genschel C, Viereck J, et al. Abstract 15057: miR-132 Inhibitor CDR 132L Attenuates Cardiac Remodeling by Exhibiting Anti-Fibrotic Effects. Circulation. 2023. doi:10.1161/circ.148.suppl_1.15057
8. Nappi F. Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25073630